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Objectives This study sought to assess outcomes in patients with ST-segment elevation myocardial in-
farction undergoing primary percutaneous coronary intervention (PCI) for unprotected left main (LM)
disease.
Background Limited data are available on outcomes in patients with ST-segment elevation myocar-
dial infarction undergoing LM PCI.
Methods Of 9,075 patients with ST-segment elevation myocardial infarction enrolled in the AMIS (Acute
Myocardial Infarction in Switzerland) Plus registry between 2005 and June 30, 2010, 6,666 underwent
primary PCI. Of them, 348 (5.2%; mean age: 63.5  12.6 years) underwent LM PCI, either isolated (n  208) or
oncomitant to PCI for other vessel segments (n  140). They were compared with 6,318 patients
94.8%; mean age: 61.9  12.5 years) undergoing PCI of non-LM vessel segments only.
esults The LM patients had higher rates of cardiogenic shock (12.2% vs. 3.5%; p  0.001), cardiac
rrest (10.6% vs. 6.3%; p  0.01), in-hospital mortality (10.9% vs. 3.8%; p  0.001), and major ad-
erse cardiac and cerebrovascular events (12.4% vs. 5.0%; p  0.001) than non-LM PCI. Rates of
ortality and major adverse cardiac and cerebrovascular events were highest for concurrent LM and
on-LM PCI (17.9% and 18.6%, respectively), intermediate for isolated LM PCI (6.3% and 8.3%, re-
pectively), and lowest for non-LM PCI (3.8% and 5.0%, respectively). Rates of mortality and major
dverse cardiac and cerebrovascular events for LM PCI were higher than for non-LM multivessel PCI
10.9% vs. 4.9%, p  0.001, and 12.4% vs. 6.4%, p  0.001, respectively). LM disease independently
redicted in-hospital death (odds ratio: 2.36; 95% conﬁdence interval: 1.34 to 4.17; p  0.003).
onclusions Emergent LM PCI in the context of acute myocardial infarction, even including 12%
ardiogenic shock, appears to have a remarkably high (89%) in-hospital survival. Concurrent LM and
on-LM PCI has worse outcomes than isolated LM PCI. (J Am Coll Cardiol Intv 2011;4:627–33)
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628Unprotected left main (LM) coronary artery disease, which
is observed in 3% to 5% of patients undergoing coronary
angiography, has major prognostic implications (1,2). Based on
early randomized trials (3,4), current guidelines (5) sup-
port the use of coronary artery bypass graft surgery in
patients with unprotected LM disease. However, recent
data show that percutaneous coronary intervention (PCI)
may be a safe and effective alternative to surgical revas-
cularization in selected patients (6 –10). However, unpro-
tected LM disease still poses a significant challenge to the
interventional cardiologist. Primary PCI has become the
standard treatment for patients presenting with acute
ST-segment elevation myocardial infarction (STEMI),
including those with LM occlusion. Unlike patients with
stable angina (8,9,11), however, limited data are available
on patients with unprotected LM disease presenting with acute
coronary syndromes (ACS) including STEMI (12–16). There-
fore, we analyzed the clinical characteristics and outcomes of
patients with STEMI treated with primary PCI for unpro-
tected LM disease who were included in the nationwide acute
myocardial infarction in Swit-
zerland AMIS (Acute Myocar-
dial Infarction in Switzerland) Plus
registry between January 1, 2005,
and June 30, 2010. These patients
were compared with patients with
STEMI treated with PCI of
other vessel segments and in-
cluded in this registry during the
same period.
Methods
Patients. The AMIS Plus regis-
try is a nationwide prospective registry of patients admitted
with ACS to 76 hospitals in Switzerland (17). The registry
was initiated in 1997, and patient recruitment has been
ongoing since then. Participating centers, ranging from
community institutions to large tertiary facilities, provide
data for each patient through a standardized Internet- or
paper-based questionnaire. The questionnaire includes 200
items addressing medical history, cardiovascular risk factors,
symptoms, out-hospital management, reperfusion therapy,
hospital course, the diagnostic test used, length of stay, and
discharge medication. Data collection is centralized at the
Institute of Social and Preventive Medicine of the University
of Zürich, and checked for consistency. Incomplete ques-
tionnaires are returned to the enrollment centers for com-
pletion. The registry was approved by the Over-Regional
Ethics Committee for Clinical Studies, the Swiss Board for
Data Security, and the appropriate Cantonal Ethic Com-
missions. AMI patients who had ST-segment elevation or
new left bundle branch block on their initial electrocardio-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
LM  left main
MACCE  major adverse
cardiac and cerebrovascular
event(s)
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctiongrams were classified as having STEMI. All patients pre-senting with STEMI and treated with primary PCI, and who
were entered into the AMIS Plus registry from January 1,
2005, to June 30, 2010, were included in the analysis. STEMI
patients were subdivided into those treated with PCI for
unprotected LM disease (LM PCI), either alone (isolated LM
PCI) or in combination with PCI of other vessel segments
(nonisolated LM PCI), and those treated with PCI of vessel
segments other than LM (non-LM PCI). The study’s primary
endpoints included in-hospital mortality and rates of major
adverse cardiac and cerebrovascular events (MACCE), defined
as cumulative composite of death, reinfarction, and cerebro-
vascular events. Bleeding was defined as major bleeding includ-
ing intracerebral hemorrhage, local bleeding requiring surgical
treatment, requirement for blood transfusions, or a drop in
blood hemoglobin of more than 3.0 g/dl.
Statistical analyses. Data are presented as the proportion of
valid cases for discrete variables and as mean  SD and/or
medians with interquartile ranges for continuous variables.
Differences in baseline characteristics were compared using the
unpaired t test or Mann-Whitney U test if appropriate and the
Pearson chi-square test. Statistics for each table are based on all
cases with valid data in the specified ranges for all variables in
each table. The 95% confidence intervals for the odds ratios
were calculated for treatment assignments and outcome using
multivariate logistic regression, with backward stepwise vari-
able selection. The following predictors were included in the
analysis: LM PCI, age, sex, history of hypertension, history of
dyslipidemia, current smoker, resuscitation, cardiogenic shock
(Killip class IV) at admission, heart rate, systemic blood
pressure, and a Charlson score2. The Charlson comorbidity
ndex takes into account the number and the seriousness of
omorbid disease (18,19). A p value 0.05 was considered
ignificant. The SPSS software (version 17.0, SPSS Inc.,
hicago, Illinois) was used for all statistical analyses.
esults
Patient population. The AMIS Plus registry included 9,075
patients admitted for STEMI to 61 Swiss hospitals between
January 1, 2005, and June 30, 2010 (Fig. 1). Of them, 7,049
patients underwent primary PCI. After exclusion of 383
patients because of incomplete data, 6,666 patients were
included in our analysis. They were subdivided into 348
patients (5.2%) treated with LM PCI and 6,318 patients
(94.8%) treated with PCI of other vessel segments
(non-LM group). Of the 348 patients in the LM group, 208
(58%) underwent isolated LM PCI and 140 patients (42%)
underwent combined PCI of LM and other vessel segments
(nonisolated LM PCI).
Baseline clinical and angiographic data. Baseline clinical and
angiographic data in the LM and non-LM PCI groups, as
well as in the isolated and nonisolated LM subgroups, are
shown in Table 1. The mean age of the overall study
population was 62.0  12.5 years. The sex distribution was
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62977% men and 23% women. The risk profile of the overall
study population was relatively high: 16.7% patients were
older than 75 years; 11.1% and 3.3% had a history of
myocardial infarction and stroke, respectively; and 3.4% had
chronic renal failure. The LM PCI patients were slightly
older, and slightly more were women compared with
non-LM PCI patients. The prevalence of cardiovascular
risk factors and comorbidities, as reflected by a Charlson
weighted index 2, was comparable in the 2 groups. The
LM PCI patients presented more frequently with dyspnea,
low left ventricular ejection fraction, cardiogenic shock,
cardiac arrest, and need for pharmacological inotropic or
mechanical (intra-aortic balloon pump) support. Median
door-to-balloon time was longer in LM versus non-LM
PCI patients (70 vs. 60 min, respectively; p  0.032).
atients with isolated LM PCI were younger and tended to
ave fewer comorbidities than those with nonisolated LM
CI did. Of nonisolated LM PCI patients, 6.9% had
isease of 1 coronary vessel besides LM, 48.1% of 2 vessels
esides LM, and 45.0% of 3 vessels besides LM. Of
on-LM PCI patients, 44.3% had 1-vessel disease, 29.9%
ad 2-vessel disease, and 25.8% had 3-vessel disease. The
umber of drug-eluting stents as a percentage of all im-
lanted stents was similar in LM PCI and non-LM PCI
atients (78.3% vs. 73.8%, respectively; p  0.09).
In-hospital outcomes. In-hospital outcomes are summarized
in Table 2. In-hospital mortality rates were higher for LM
than non-LM PCI patients (10.9% vs. 3.8%; p  0.001),
as were in-hospital rates of MACCE (12.4% vs. 5.0%;
Figure 1. Study Flow Diagram
The ﬂow chart shows the breakdown of included and excluded patients. AMIS
coronary intervention; STEMI  ST-segment elevation myocardial infarction.p  0.001), and the proportion of patients presentingwith cardiogenic shock on admission (12.2% vs. 3.5%;
p  0.001). In both groups, in-hospital mortality was
extremely high in patients presenting with cardiogenic
shock on admission, with a significant difference between
LM and non-LM PCI (54.8% vs. 35.5%, respectively;
p  0.024). Patients developing cardiogenic shock after
admission during hospitalization also were more frequent
in the LM versus non-LM PCI group (6.1% vs. 3.3%;
p  0.01), although the associated in-hospital mortality
rates were similar (38.0% and 38.1%, respectively).
Among hemodynamically stable (Killip classes I to III)
patients on admission, in-hospital mortality associated
with LM PCI (5.0%) was almost twice as high as in the
non-LM PCI group (2.7%). Rates of reinfarction, cere-
brovascular events, and bleeding were similar for LM and
non-LM PCI. Subgroup analysis of patients treated for
LM PCI showed higher in-hospital mortality rates
(17.9% vs. 6.3%; p  0.001) and higher rates of MACCE
(18.6% vs. 8.3%; p  0.007) in those treated with
concurrent PCI of LM and other vessel segments (i.e.,
nonisolated LM) compared with isolated LM PCI. These
differences remained significant even when the analysis was
restricted to the subgroup of non-LM patients who underwent
PCI of multiple vessels (mortality: 4.9%, rates of MACCE:
6.4%; p 0.001 vs. LM PCI for both parameters). An additional
subgroup analysis based on age showed approximately 2- and
4-fold increases in death rates in the LM PCI and non-LM PCI
groups, respectively, for patients aged 75 years compared with
younger ones. In elderly patients, however, death rates in LM PCI
ute Myocardial Infarction in Switzerland; LM  left main; PCI  percutaneous Acpatients were still approximately 2-fold higher than in non-LM
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630PCI patients (p  0.026). Similarly, elderly patients showed
increased rates of MACCE, compared with younger ones, in
both the LM PCI and the non-LM PCI groups.
Multivariable analysis. Results of multivariable logistic re-
ression analysis are shown in Table 3. This analysis
dentified LM PCI, age, cardiogenic shock (Killip class IV),
ardiac resuscitation, tachycardia, low systolic blood pres-
ure, and an elevated Charlson weighted index as indepen-
Table 1. Clinical and Angiographic Data at Baseline
LM PCI
(n  348)
Non-LM PCI
(n  6,318)
Demographics
Age, yrs 63.5 12.6 61.9 12.5
Women 87/348 (25.0) 1,455/6,318 (23.0)
Clinical presentation
Chest pain 295/332 (88.9) 5,572/6,130 (90.9)
Dyspnea 107/307 (34.9) 1,287/5,507 (23.4)
Resuscitation before admission 37/348 (10.6) 400/6,318 (6.3)
Killip class I 241/344 (70.1) 5,408/6,279 (86.1)
Killip class II 44/344 (12.8) 532/6,279 (8.5)
Killip class III 17/344 (4.9) 122/6,279 (1.9)
Cardiogenic shock at admission 42/344 (12.2) 217/6,279 (3.5)
Charlson weighted index 2 50/340 (14.7) 843/6,152 (13.7)
Times, min
Symptom-to-admission 187 (91, 485) 180 (100,
Median door-to-balloon 70 (23, 149) 60 (24, 2
Risk factors
Family history of CAD 94/300 (31.3) 1,884/5,539 (34.0)
Hypertension 174/318 (54.7) 3,215/5,909 (54.4)
Dyslipidemia 142/295 (48.1) 2,764/5,519 (50.1)
Diabetes 57/324 (17.6) 919/5,992 (15.3)
Smoking, current 126/314 (40.1) 2,691/5,748 (46.8)
Obesity, BMI 30 kg/m2 61/265 (23.0) 1,065/5,367 (19.8)
Angiographic data
1-vessel disease — 2,788/6,290 (44.3)
2-vessel disease — 1,882/6,290 (29.9)
3-vessel disease — 1,620/6,290 (25.8)
Drug therapy
Acetylsalicylic acid 337/346 (97.4) 6,205/6,306 (98.4)
Clopidogrel 301/346 (87.0) 5,872/6,294 (93.3)
GP IIb/IIIa inhibitors 108/339 (31.9) 2,755/6,232 (44.2)
Beta-blocker 207/344 (60.2) 4,132/6,238 (66.2)
ACE inhibitor 177/343 (51.6) 3,489 (56.2)
Calcium-channel blocker 9/340 (2.6) 297/6,183 (4.8)
Diuretic 62/343 (18.1) 944/6,212 (15.2)
HMG-CoA reductase Inhibitors 246/345 (71.3) 5,100/6,257 (81.5)
Circulatory support
IABP 48/343 (14.0) 400/6,244 (6.4)
Vasopressor 56/341 (16.4) 641/6,194 (10.3)
Values are mean SD, n/N (%), or median (IQR). Data are shown for LM versus non-LM PCI and isol
ACE angiotensin-converting enzyme; BMIbodymass index; CAD coronary artery disease; G
IQR interquartile range; LM left main; PCI percutaneous coronary intervention.ent predictors of in-hospital mortality.iscussion
PCI for unprotected LM disease has been performed with
increasing frequency over the past decade. However, unpro-
tected LM disease still poses a significant challenge to the
interventional cardiologist, particularly with respect to pri-
mary PCI in patients with STEMI. Limited data are available
on these patients. Here, we report on the largest series, to the
p Value
Isolated LM PC
(n  208)
Nonisolated LM PCI
(n  140) p Value
0.021 61.7 12.5 66.2 12.3 0.001
0.40 53/208 (25.5) 34/140 (24.3) 0.90
0.21 181/202 (89.6) 114/130 (87.7) 0.60
0.001 58/183 (31.7) 49/124 (39.5) 0.18
0.004 16/208 (7.7) 21/140 (15.0) 0.034
0.001 158/206 (76.7) 83/138 (60.1) 0.001
0.008 21/206 (10.2) 23/138 (16.7) 0.099
0.001 7/206 (3.4) 10/138 (7.2) 0.13
0.001 20/206 (9.7) 22/138 (15.9) 0.09
0.57 20/204 (9.8) 30/136 (22.1) 0.003
0.40 186 (88, 488) 210 (120, 420) 0.46
0.032 70 (22, 158) 69 (27, 143) 0.88
0.35 56/184 (30.4) 38/116 (32.8) 0.70
0.95 97/192 (50.5) 77/126 (61.1) 0.067
0.55 81/175 (46.3) 61/120 (50.8) 0.48
0.27 31/194 (16.0) 26/130 (20.0) 0.37
0.023 79/190 (41.6) 47/124 (37.9) 0.56
0.21 38/166 (22.9) 23/99 (23.2) 0.99
— — 9/131 (6.9) —
— — 63/131 (48.1) —
— — 59/131 (45.0) —
0.19 203/206 (98.5) 134/140 (95.7) 0.17
0.001 181/206 (87.9) 120/140 (85.7) 0.63
0.001 70/203 (34.5) 38/136 (27.9) 0.24
0.023 133/207 (64.3) 74/137 (54.0) 0.072
0.11 120/207 (58.0) 57/136 (41.9) 0.004
0.07 3/204 (1.5) 6/136 (4.4) 0.16
0.17 30/204 (14.7) 32/139 (23.0) 0.063
0.001 159/206 (77.2) 87/139 (62.6) 0.004
0.001 18/206 (8.7) 30/137 (21.9) 0.001
0.001 181/206 (87.9) 120/140 (85.7) 0.63
versus nonisolated LM PCI.
coprotein; HMG-CoA 3-hydroxy-3-methylglutaryl coenzymeA; IABP intra-aortic balloonpump;390)
40)
ated LM
Pglybest of our knowledge, of patients with STEMI treated with
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631primary LM PCI. Our results show that emergent LM PCI in
the context of acute myocardial infarction, even including 12%
cardiogenic shock, appears to have a remarkably high (89%)
in-hospital survival. Nevertheless, patients with LM PCI had
worse in-hospital outcomes than those treated with PCI of
vessel segments other than LM. Of note, this difference
Table 2. In-Hospital Outcomes
LM PCI Non-L
All patients n 348 n
In-hospital death 38/348 (10.9) 241/6,3
In-hospital death, patients with CS at admission 23/42 (54.8) 77/2
MACCE, death, reinfarction, stroke 43/346 (12.4) 314/6,2
CS developing during hospitalization 21/346 (6.1) 205/6,2
Reinfarction 4/346 (1.2) 56/6,2
Cerebrovascular events 5/346 (1.4) 42/6,2
Bleeding 10/346 (2.9) 180/6,2
Patients age 75 yrs n 274 n
In-hospital death 25/274 (9.1) 142/5,2
In-hospital death, patients with CS at admission 17/33 (51.5) 60/1
MACCE, death, reinfarction, stroke 29/272 (10.7) 198/5,2
CS developing during hospitalization 17/237 (7.2) 139/5,0
Reinfarction 4/272 (1.5) 39/5,2
Cerebrovascular events 4/272 (1.5) 32/5,2
Bleeding 5/272 (1.8) 138/5,2
Patients age 75 yrs n 74 n
In-hospital death 13/74 (17.6) 99/1,0
In-hospital death, patients with CS at admission 6/9 (66.7) 17/
MACCE, death, reinfarction, stroke 14/74 (18.9) 116/1,0
CS developing during hospitalization 4/63 (6.3) 58/9
Reinfarction 0/74 (0) 17/1,0
Cerebrovascular events 1/74 (1.4) 10/1,0
Bleeding 5/74 (6.8) 42/1,0
Values are n/N (%). Data are shown for LM versus non-LM PCI groups and isolated LM versus noniso
CS cardiogenic shock; MACCEmajor adverse cardiac and cerebrovascular event(s); other ab
Table 3. Multivariable Analysis Models: Independent Predictors of
In-Hospital Mortality in Patients With ACS Treated With Early PCI
Variable Odds Ratio (95% CI) p Value
Cardiogenic shock at admission 4.87 (2.84–8.35) 0.001
Resuscitation 4.20 (2.60–6.77) 0.001
Charlson index 2* 2.66 (1.76–4.02) 0.001
Left main treated 2.36 (1.34–4.17) 0.003
Age, per 10-yr increase 1.96 (1.62–2.37) 0.001
Heart rate, per 10 beats/min increase 1.23 (1.14–1.33) 0.001
Systolic BP, per 5 mm Hg increase 0.88 (0.85–0.91) 0.001
All covariates were assessed at admission. *The Charlson comorbidity index gives an estimate of
survival based on the following variables: cerebrovascular disease, chronic pulmonary disease,
congestive heart failure, connective tissue disease, dementia, hemiplegia, leukemia, malignant
lymphoma, myocardial infarction, peripheral vascular disease, ulcer disease, diabetes mellitus,
liver disease, renal disease, malignant solid tumor, and acquired immune deficiency syndrome
status.
ACS acute coronary syndrome(s); BP blood pressure; CI confidence interval;PCI percutaneous coronary intervention.persisted when the analysis was restricted to the subset of
non-LM PCI patients with multivessel disease. By multivari-
able logistic regression analysis, LM disease was identified as
an independent risk factor in patients with STEMI treated
with primary PCI.
An earlier report by Lee et al. (12) showed an 8%
in-hospital mortality in 62 patients with ACS treated with
LM PCI, compared with 10.9% in our patients with
STEMI and LM PCI. Buszman et al. (16) reported a
12-month mortality of 6.3% in patients with non-STEMI
treated with LM PCI. In a registry study, Montalescot et al.
(13) reported an 11% in-hospital mortality in the subgroup
of LM patients treated with PCI, very similar to the
mortality rate in our study (10.9%). However, these earlier
studies focused on patients with ACS (12,13) or non-
STEMI (16), whereas our analysis was restricted to patients
with STEMI. Moreover, in the registry study by Montale-
scot et al. (13), only 47% of the LM PCI patients underwent
the procedure on the same day of symptom onset, whereas
our analysis was restricted to patients treated with primary
PCI. Another difference with this earlier study is that 92%
of the LM PCI patients in this study had a concomitant
disease of another coronary territory (13), whereas a major-
p Value Isolated LM PCI Nonisolated LM PCI p Value
n 208 n 140
) 0.001 13/208 (6.3) 25/140 (17.9) 0.001
5) 0.024 11/20 (55.0) 12/22 (54.5) 1.0
) 0.001 17/206 (8.3) 26/140 (18.6) 0.007
) 0.01 10/206 (4.9) 11/140 (7.9) 0.26
) 0.55 3/206 (1.5) 1/140 (0.7) 0.65
) 0.10 2/206 (1.0) 3/140 (2.1) 0.40
) 0.87 3/206 (1.5) 7/140 (5.0) 0.097
n 174 n 100
) 0.001 10/174 (5.7) 15/100 (15.0) 0.015
0) 0.049 8/15 (53.3.0) 9/18 (50.0) 1.0
) 0.001 13/172 (7.6) 16/100 (16.0) 0.041
) 0.01 8/156 (5.1) 9/81 (11.1) 0.11
) 0.16 3/172 (1.7) 1/100 (1.0) 1.00
) 0.10 1/172 (0.6) 3/100 (3.0) 0.14
) 0.56 2/172 (1.2) 3/100 (3.0) 0.36
n 34 n 40
) 0.026 3/34 (8.8) 10/40 (25.0) 0.12
6) 0.46 3/5 (60.0) 3/4 (75.0) 1.0
2) 0.059 4/34 (11.8) 10/40 (25.0) 0.23
) 0.78 2/28 (7.1) 2/35 (5.7) 1.0
) 0.62 0/34 (0) 0/40 (0)
) 0.53 1/34 (2.9) 0/40 (0) 0.46
) 0.24 1/34 (2.9) 4/40 (10.0) 0.37
M PCI subgroups.
ons as in Table 1.M PCI
6,318
18 (3.8
17 (35.
91 (5.0
89 (3.3
89 (0.9
89 (0.7
89 (2.9
5,278
78 (2.7
82 (33.
55 (3.8
44 (2.8
55 (0.7
55 (0.6
55 (2.6
1,040
40 (9.5
35 (48.
36 (11.
91 (5.9
34 (1.6
34 (1.0
34 (4.1
lated Lity of our LM PCI patients had isolated LM PCI.
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632Cardiogenic shock on admission, which was observed in
more than 10% of our patients, was the main determinant of
death in patients with STEMI treated with LM PCI, with
an intrinsic mortality of approximately 50%. By contrast,
mortality in hemodynamically stable LM PCI patients was
nearly twice as high as in hemodynamically stable non-LM
PCI patients, reflecting the prognostic impact of LM
disease. With respect to the role of cardiogenic shock in this
clinical setting, Hurtado et al. (15) reported a 66% preva-
lence of cardiogenic shock and a 61% in-hospital mortality
in 71 consecutive patients treated with emergency PCI for
LM disease. These data are in line with our results,
highlighting the poor prognosis associated with cardiogenic
shock (20) and the key role of an appropriate pharmacolog-
ical and mechanical hemodynamic support, when needed.
In the present study, patients treated with concurrent
PCI of LM and other vessel segments were at an 3-fold
increased risk compared with those treated with isolated
LM PCI. The latter were at a 2-fold increased risk
compared with those treated with non-LM PCI. Interest-
ingly, the prognostic role of isolated LM disease in patients
with STEMI was moderate. By contrast, the prognostic
impact of LM disease was greatest in the presence of
additional lesions on other vessel segments. Of note, this
subgroup of patients had a higher prevalence of multivessel
disease, irrespective of LM lesions, compared with non-LM
PCI patients, suggesting that LM disease might reflect an
overall higher degree and a more widespread pattern of
anatomical lesions in the former subgroup.
Not surprisingly, age was a major determinant of clinical
outcomes. In patients age 75 years presenting with cardio-
genic shock on admission, mortality was as high as 60% in
patients with isolated LM PCI, and as high as 75% in those
with nonisolated LM PCI, while being lower in younger
patients. These results are of major interest because few studies
have adequately described the impact of different treatment
modalities in older patients with STEMI (21). Our results are
in line with data from the SHOCK (Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock?)
trial (22) showing that older patients (age 75 years) present-
ng with AMI complicated by cardiogenic shock and treated
ith early revascularization have nearly double the 30-day
ortality of younger patients (75.0% and 41.4%, respectively).
ecent data clearly demonstrate the benefits of the invasive
anagement of ACS in older patients (23).
Unprotected LM disease is a heterogeneous condition
hat includes various degrees of anatomic location and
everity of LM lesions, and various possible sets of concur-
ent lesions of other coronary segments (24). In the AMIS
lus registry, patients were classified based on the vessel
reated by PCI, rather than based solely on angiographic
ata, and the decision to perform PCI was at the discretion
f the operator. Over the past 5 years, critical LM lesions in
atients with STEMI have increasingly been managednvasively, more often with PCI than with coronary artery
ypass graft surgery (24). Therefore, it seems reasonable to
ssume that, in patients with STEMI who underwent
rimary PCI and were enrolled in the AMIS Plus registry,
ery few LM stenoses, if any, were left untreated. It also
hould be emphasized that our analysis included a large
ubgroup of patients who underwent isolated LM PCI,
nequivocally defining LM stenosis as the culprit lesion.
oreover, LM disease appeared to be associated with an
ncreased risk even before undergoing primary PCI, as
ndicated by elevated resuscitation rates and a higher Charl-
on weighted index on admission.
Current guidelines (25) support PCI of non–infarct-
elated arteries during primary PCI in patients with STEMI
nd hemodynamic instability, whereas its role in hemody-
amically stable patients remains more controversial (26,27).
ur analysis provides important data on the outcomes of
atients with STEMI undergoing simultaneous PCI of LM
nd other vessel segments, showing highest mortality and
ACCE rates in this subgroup. Current strategies in patients
ith STEMI favor single-vessel acute PCI as the default
pproach (to treat only the infarct-related artery during the
cute phase of STEMI), whereas acute multivessel PCI is
estricted to exceptional patients with multiple critical (90%)
nd potentially unstable lesions, and significant lesions of the
oninfarct arteries being treated either medically or by staged
evascularization procedures (28). Although these recommen-
ations referred to multivessel disease in general, they appear to
lso apply to the management of non-LM lesions in the
ontext of acute LM PCI.
Study limitations. Finally, a few limitations of our study,
hich are related to its nature of a registry study, must be
cknowledged. Although the AMIS Plus registry provides
ata on the number of vessels treated with PCI, the precise
natomical distribution of the lesions is unknown. Clearly, it
ould have been of interest to know how LM lesions were
istributed across the LM itself, including or not the bifurca-
ion, and whether additional lesions were located on the right
oronary artery versus the left anterior descending and/or the
ircumflex coronary artery. It also would have been of interest
o know how many patients underwent LM PCI after having
een rejected for coronary artery bypass graft surgery. Although
e do not have precise data on this issue, these patients most
ikely constituted a small minority of all LM patients. An
dditional limitation is that patients who died before planned
CI were not included in the analysis.
onclusions
Our data indicate that emergent LM PCI in the context of
acute myocardial infarction has a remarkably high overall
in-hospital survival, despite specific subsets of patients
(including old, hemodynamically unstable patients, and
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633those undergoing concurrent LM and non-LM PCI) hav-
ing a significantly increased risk.
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